Siemens Healthineers completes acquisition of Varian

246

siemensSiemens Healthineers AG has completed the acquisition of Varian Medical Systems, Inc. The acquisition was previously announced on 2 August 2020.

With Varian, Siemens Healthineers has the most comprehensive portfolio in the MedTech sector, which offers the company considerable potential for value creation. With a highly integrated approach, Siemens Healthineers will take the global fight against cancer to a new level,” says Ralf P Thomas, chair of the Supervisory Board of Siemens Healthineers AG.

With the completion of this transaction, we are now best-positioned to take two leaps together: a leap in cancer care and a leap in our impact on healthcare overall. Together, we are establishing a strong and trusted partner capable of supporting customers and patients along the entire cancer care continuum as well as through all major clinical pathways,” comments Bernd Montag, CEO of Siemens Healthineers AG.

Chris Toth, CEO of Varian, adds: “Through the transformative combination of Varian and Siemens Healthineers, our united company will address the growing need for personalised, data-driven diagnosis and precision cancer care that enables us to fight back against globally increasing cancer rates. By bringing together our unique and highly complementary portfolios and capabilities, we will support oncology clinicians and patients in achieving better outcomes and move even closer to achieving our vision of a world without fear of cancer.”

According to a company press release, the acquisition of Varian will allow Siemens Healthineers to leverage AI-assisted analytics to advance the development and delivery of data-driven precision care and redefine cancer diagnosis, care delivery, and post-treatment survivorship. Through early and accurate detection as well as more efficient diagnosis, increased treatment quality and access, Siemens Healthineers will support and accelerate Varian’s mission to reduce uncertainty for cancer patients and increase the level of cancer survivorship.

Varian’s common stock ceased trading on the New York Stock Exchange prior to the opening of trading today.


LEAVE A REPLY

Please enter your comment!
Please enter your name here